Microbiota modification by probiotic supplementation reduces colitis associated colon cancer in mice

World Journal of Gastroenterology

Volumn 24, Issue 18, 2018, Pages 1995-2008

  Mendes, Maria Carolina S ^a   Paulino, Daiane S M ^a   Brambilla, Sandra R ^a   Camargo, Juliana A ^a   Persinoti, Gabriela F ^b   Carvalheira, José Barreto C ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b BRAZILIAN CENTER FOR RESEARCH IN ENERGY AND MATERIALS CNPEM   (Brazil)

Author keywords

Bifidobacterium bifidum; Chemoprevention; Intestinal microbiota; Lactobacillus acidophilus; Lactobacillus rhamnosus

Indexed keywords

CYTOKINE; EOTAXIN; INTERLEUKIN 10; PROBIOTIC AGENT; RANTES; RNA 16S; TUMOR NECROSIS FACTOR; AZOXYMETHANE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIFIDOBACTERIUM BIFIDUM; C57BL 6 MOUSE; COLITIS; COLON CANCER; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; EXPERIMENTAL MODEL; HISTOLOGY; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MALE; MOUSE; NONHUMAN; POPULATION ABUNDANCE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SPECIES COMPOSITION; SPECIES DIVERSITY; SPECIES RICHNESS; TUMOR MICROENVIRONMENT; TUMOR VOLUME; ANIMAL; BIFIDOBACTERIUM; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; COLON; COLON TUMOR; DISEASE MODEL; HUMAN; INTESTINE MUCOSA; ISOLATION AND PURIFICATION; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY;

ANIMALS; AZOXYMETHANE; BIFIDOBACTERIUM; COLITIS; COLON; COLONIC NEOPLASMS; CYTOKINES; DISEASE MODELS, ANIMAL; GASTROINTESTINAL MICROBIOME; HUMANS; INTESTINAL MUCOSA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MALE; MICE; MICE, INBRED C57BL; PROBIOTICS; RNA, RIBOSOMAL, 16S;

EID: 85047017761     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v24.i18.1995     Document Type: Article

References (58)

1. Nosho K, Sukawa Y, Adachi Y, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yamamoto IIT, Ishigami K, Igarashi H, Maruyama R, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. World J Gastroenterol 2016;22:557-566 [PMID: 26811607 DOI: 10.3748/wjg.v22.i2.557]
2. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-899 [PMID: 20303878 DOI: 10.1016/j.cell.2010.01.025]
3. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-674 [PMID: 21376230 DOI: 10.1016/j.cell.2011.02.013]
4. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science 2012;336:1268-1273 [PMID: 22674334 DOI: 10.1126/science.1223490]
5. Zhu Q, Gao R, Wu W, Qin H. The role of gut microbiota in the pathogenesis of colorectal cancer. Tumour Biol 2013;34:1285-1300 [PMID: 23397545 DOI: 10.1007/s13277-013-0684-4]
6. O'Keefe SJ. Diet, microorganisms and their metabolites, and colon cancer. Nat Rev Gastroenterol Hepatol 2016;13:691-706 [PMID: 27848961 DOI: 10.1038/nrgastro.2016.165]
7. Tennyson CA, Friedman G. Microecology, obesity, and probiotics. Curr Opin Endocrinol Diabetes Obes 2008;15:422-427 [PMID: 18769213 DOI: 10.1097/MED.0b013e328308dbfb]
8. Tamburini S, Shen N, Wu HC, Clemente JC. The microbiome in early life: implications for health outcomes. Nat Med 2016;22:713-722 [PMID: 27387886 DOI: 10.1038/nm.4142]
9. Brennan CA, Garrett WS. Gut Microbiota, Inflammation, and Colorectal Cancer. Annu Rev Microbiol 2016;70:395-411 [PMID: 27607555 DOI: 10.1146/annurev-micro-102215-095513]
10. Hill C, Guarner F, Reid G, Gibson GR, Merenstein DJ, Pot B, Morelli L, Canani RB, Flint HJ, Salminen S, Calder PC, Sanders ME. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514 [PMID: 24912386 DOI: 10.1038/nrgastro.2014.66]
11. Mantovani A. From phagocyte diversity and activation to probiotics: back to Metchnikoff. Eur J Immunol 2008;38:3269-3273 [PMID: 19039773 DOI: 10.1002/eji.200838918]
12. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: Updated systematic review with meta-analysis. World J Gastroenterol 2015;21:3072-3084 [PMID: 25780308 DOI: 10.3748/wjg.v21.i10.3072]
13. Kim JY, Kwon JH, Ahn SH, Lee SI, Han YS, Choi YO, Lee SY, Ahn KM, Ji GE. Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebocontrolled trial. Pediatr Allergy Immunol 2010;21:e386-e393 [PMID: 19840300 DOI: 10.1111/j.1399-3038.2009.00958.x]
14. King S, Glanville J, Sanders ME, Fitzgerald A, Varley D. Effectiveness of probiotics on the duration of illness in healthy children and adults who develop common acute respiratory infectious conditions: a systematic review and meta-analysis. Br J Nutr 2014;112:41-54 [PMID: 24780623 DOI: 10.1017/S0007114514000075]
15. Mennini M, Dahdah L, Artesani MC, Fiocchi A, Martelli A. Probiotics in Asthma and Allergy Prevention. Front Pediatr 2017;5:165 [PMID: 28824889 DOI: 10.3389/fped.2017.00165]
16. Sun J, Buys NJ. Glucose- and glycaemic factor-lowering effects of probiotics on diabetes: a meta-analysis of randomised placebocontrolled trials. Br J Nutr 2016;115:1167-1177 [PMID: 26899960 DOI: 10.1017/S0007114516000076]
17. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer 2013;13:800-812 [PMID: 24132111 DOI: 10.1038/nrc3610]
18. Bienenstock J, Gibson G, Klaenhammer TR, Walker WA, Neish AS. New insights into probiotic mechanisms: a harvest from functional and metagenomic studies. Gut Microbes 2013;4:94-100 [PMID: 23249742 DOI: 10.4161/gmic.23283]
19. Orlando A, Russo F. Intestinal microbiota, probiotics and human gastrointestinal cancers. J Gastrointest Cancer 2013;44:121-131 [PMID: 23180023 DOI: 10.1007/s12029-012-9459-1]
20. Bron PA, Kleerebezem M, Brummer RJ, Cani PD, Mercenier A, MacDonald TT, Garcia-Ródenas CL, Wells JM. Can probiotics modulate human disease by impacting intestinal barrier function? Br J Nutr 2017;117:93-107 [PMID: 28102115 DOI: 10.1017/S0007114516004037]
21. Geier MS, Butler RN, Howarth GS. Probiotics, prebiotics and synbiotics: a role in chemoprevention for colorectal cancer? Cancer Biol Ther 2006;5:1265-1269 [PMID: 16969130 DOI: 10.4161/cbt.5.10.3296]
22. Thomas CM, Versalovic J. Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes 2010;1:148-163 [PMID: 20672012 DOI: 10.4161/gmic.1.3.11712]
23. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-296 [PMID: 15294155 DOI: 10.1016/j.cell.2004.07.013]
24. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon reads. Nat Methods 2013;10:996-998 [PMID: 23955772 DOI: 10.1038/nmeth.2604]
25. McMurdie PJ, Holmes S. Waste not, want not: why rarefying microbiome data is inadmissible. PLoS Comput Biol 2014;10:e1003531 [PMID: 24699258 DOI: 10.1371/journal.pcbi.1003531]
26. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-249 [PMID: 8350599]
27. Urbanska AM, Bhathena J, Martoni C, Prakash S. Estimation of the potential antitumor activity of microencapsulated Lactobacillus acidophilus yogurt formulation in the attenuation of tumorigenesis in Apc (Min/+) mice. Dig Dis Sci 2009;54:264-273 [PMID: 18633708 DOI: 10.1007/s10620-008-0363-2]
28. Gamallat Y, Meyiah A, Kuugbee ED, Hago AM, Chiwala G, Awadasseid A, Bamba D, Zhang X, Shang X, Luo F, Xin Y. Lactobacillus rhamnosus induced epithelial cell apoptosis, ameliorates inflammation and prevents colon cancer development in an animal model. Biomed Pharmacother 2016;83:536-541 [PMID: 27447122 DOI: 10.1016/j.biopha.2016.07.001]
29. Jacouton E, Chain F, Sokol H, Langella P, Bermúdez-Humarán LG. Probiotic Strain Lactobacillus casei BL23 Prevents Colitis-Associated Colorectal Cancer. Front Immunol 2017;8:1553 [PMID: 29209314 DOI: 10.3389/fimmu.2017.01553]
30. Kuugbee ED, Shang X, Gamallat Y, Bamba D, Awadasseid A, Suliman MA, Zang S, Ma Y, Chiwala G, Xin Y, Shang D. Structural Change in Microbiota by a Probiotic Cocktail Enhances the Gut Barrier and Reduces Cancer via TLR2 Signaling in a Rat Model of Colon Cancer. Dig Dis Sci 2016;61:2908-2920 [PMID: 27384052 DOI: 10.1007/s10620-016-4238-7]
31. Gueimonde M, Ouwehand A, Huhtinen H, Salminen E, Salminen S. Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 2007;13:3985-3989 [PMID: 17663515 DOI: 10.3748/wjg.v13.i29.3985]
32. Wang X, Yang Y, Huycke MM. Microbiome-driven carcinogenesis in colorectal cancer: Models and mechanisms. Free Radic Biol Med 2017;105:3-15 [PMID: 27810411 DOI: 10.1016/j.freeradbio med.2016.10.504]
33. Thomas AM, Jesus EC, Lopes A, Aguiar S Jr, Begnami MD, Rocha RM, Carpinetti PA, Camargo AA, Hoffmann C, Freitas HC, Silva IT, Nunes DN, Setubal JC, Dias-Neto E. Tissue-Associated Bacterial Alterations in Rectal Carcinoma Patients Revealed by 16S rRNA Community Profiling. Front Cell Infect Microbiol 2016;6:179 [PMID: 28018861 DOI: 10.3389/fcimb.2016.00179]
34. Gao R, Kong C, Huang L, Li H, Qu X, Liu Z, Lan P, Wang J, Qin H. Mucosa-associated microbiota signature in colorectal cancer. Eur J Clin Microbiol Infect Dis 2017;36:2073-2083 [PMID: 28600626 DOI: 10.1007/s10096-017-3026-4]
35. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003;361:512-519 [PMID: 12583961 DOI: 10.1016/S0140-6736 (03) 12489-0]
36. Chen W, Liu F, Ling Z, Tong X, Xiang C. Human intestinal lumen and mucosa-associated microbiota in patients with colorectal cancer. PLoS One 2012;7:e39743 [PMID: 22761885 DOI: 10.1371/journal.pone.0039743]
37. Verma A, Shukla G. Probiotics Lactobacillus rhamnosus GG, Lactobacillus acidophilus suppresses DMH-induced procarcinogenic fecal enzymes and preneoplastic aberrant crypt foci in early colon carcinogenesis in Sprague Dawley rats. Nutr Cancer 2013;65:84-91 [PMID: 23368917 DOI: 10.1080/01635581.2013.741746]
38. Verma A, Shukla G. Synbiotic (Lactobacillus rhamnosus + Lactobacillus acidophilus+inulin) attenuates oxidative stress and colonic damage in 1, 2 dimethylhydrazine dihydrochloride-induced colon carcinogenesis in Sprague-Dawley rats: a long-term study. Eur J Cancer Prev 2014;23:550-559 [PMID: 25025584 DOI: 10.1097/CEJ.0000000000000054]
39. Gosai V, Ambalam P, Raman M, Kothari CR, Kothari RK, Vyas BR, Sheth NR. Protective effect of Lactobacillus rhamnosus 231 against N-Methyl-N'-nitro-N-nitrosoguanidine in animal model. Gut Microbes 2011;2:319-325 [PMID: 22157237 DOI: 10.4161/gmic.18755]
40. Zahran WE, Elsonbaty SM, Moawed FSM. Lactobacillus rhamnosus ATCC 7469 exopolysaccharides synergizes with low level ionizing radiation to modulate signaling molecular targets in colorectal carcinogenesis in rats. Biomed Pharmacother 2017;92:384-393 [PMID: 28554134 DOI: 10.1016/j.biopha.2017.05.089]
41. Cani PD, de Vos WM. Next-Generation Beneficial Microbes: The Case of Akkermansia muciniphila. Front Microbiol 2017;8:1765 [PMID: 29018410 DOI: 10.3389/fmicb.2017.01765]
42. Chen H, Xia Y, Zhu S, Yang J, Yao J, Di J, Liang Y, Gao R, Wu W, Yang Y, Shi C, Hu D, Qin H, Wang Z. Lactobacillus plantarum LP-Onlly alters the gut flora and attenuates colitis by inducing microbiome alteration in interleukin-10 knockout mice. Mol Med Rep 2017;16:5979-5985 [PMID: 28849048 DOI: 10.3892/mmr.2017.7351]
43. Shi CZ, Chen HQ, Liang Y, Xia Y, Yang YZ, Yang J, Zhang JD, Wang SH, Liu J, Qin HL. Combined probiotic bacteria promotes intestinal epithelial barrier function in interleukin-10-genedeficient mice. World J Gastroenterol 2014;20:4636-4647 [PMID: 24782616 DOI: 10.3748/wjg.v20.i16.4636]
44. Vigsnæs LK, Brynskov J, Steenholdt C, Wilcks A, Licht TR. Gram-negative bacteria account for main differences between faecal microbiota from patients with ulcerative colitis and healthy controls. Benef Microbes 2012;3:287-297 [PMID: 22968374 DOI: 10.3920/BM2012.0018]
45. Weir TL, Manter DK, Sheflin AM, Barnett BA, Heuberger AL, Ryan EP. Stool microbiome and metabolome differences between colorectal cancer patients and healthy adults. PLoS One 2013;8:e70803 [PMID: 23940645 DOI: 10.1371/journal.pone.0070803]
46. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A, Young VB, Henrissat B, Wilmes P, Stappenbeck TS, Núñez G, Martens EC. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell 2016;167:1339-1353. e21 [PMID: 27863247 DOI: 10.1016/j.cell.2016.10.043]
47. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, Derrien M, Muccioli GG, Delzenne NM, de Vos WM, Cani PD. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013;110:9066-9071 [PMID: 23671105 DOI: 10.1073/pnas.1219451110]
48. Kang CS, Ban M, Choi EJ, Moon HG, Jeon JS, Kim DK, Park SK, Jeon SG, Roh TY, Myung SJ, Gho YS, Kim JG, Kim YK. Extracellular vesicles derived from gut microbiota, especially Akkermansia muciniphila, protect the progression of dextran sulfate sodium-induced colitis. PLoS One 2013;8:e76520 [PMID: 24204633 DOI: 10.1371/journal.pone.0076520]
49. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon. J Nutr Biochem 2008;19:587-593 [PMID: 18061431 DOI: 10.1016/j.jnutbio.2007.08.002]
50. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer. Nat Rev Microbiol 2014;12:661-672 [PMID: 25198138 DOI: 10.1038/nrmicro3344]
51. Donkor ON, Ravikumar M, Proudfoot O, Day SL, Apostolopoulos V, Paukovics G, Vasiljevic T, Nutt SL, Gill H. Cytokine profile and induction of T helper type 17 and regulatory T cells by human peripheral mononuclear cells after microbial exposure. Clin Exp Immunol 2012;167:282-295 [PMID: 22236005 DOI: 10.1111/j.1365-2249.2011.04496.x]
52. Dai C, Zheng CQ, Meng FJ, Zhou Z, Sang LX, Jiang M. VSL#3 probiotics exerts the anti-inflammatory activity via PI3k/Akt and NF-κB pathway in rat model of DSS-induced colitis. Mol Cell Biochem 2013;374:1-11 [PMID: 23271629 DOI: 10.1007/s11010-012-1488-3]
53. Hakansson A, Molin G. Gut microbiota and inflammation. Nutrients 2011;3:637-682 [PMID: 22254115 DOI: 10.3390/nu3060637]
54. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011;317:664-673 [PMID: 21134366 DOI: 10.1016/j.yexcr.2010.11.013]
55. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 2004;16:1201-1210 [PMID: 15337520 DOI: 10.1016/j.cellsig.2004.04.007]
56. Aldinucci D, Colombatti A. The inflammatory chemokine CCL5 and cancer progression. Mediators Inflamm 2014;2014:292376 [PMID: 24523569 DOI: 10.1155/2014/292376]
57. Matthews AN, Friend DS, Zimmermann N, Sarafi MN, Luster AD, Pearlman E, Wert SE, Rothenberg ME. Eotaxin is required for the baseline level of tissue eosinophils. Proc Natl Acad Sci USA 1998;95:6273-6278 [PMID: 9600955 DOI: 10.1073/pnas.95.11.6273]
58. Zezos P, Patsiaoura K, Nakos A, Mpoumponaris A, Vassiliadis T, Giouleme O, Pitiakoudis M, Kouklakis G, Evgenidis N. Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy. Colorectal Dis 2014;16:O420-O430 [PMID: 25040651 DOI: 10.1111/codi.12725]